Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Enoblituzumab Schedule 1 · 1 trial · 4 indications
Dose-limiting toxicities are severe side effects related to study treatment that may cause dose interruptions, dose reductions, or withdrawal of treatment.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Enoblituzumab 3 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks |
| Cohort 2 | EXPERIMENTAL | Enoblituzumab 10 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks |
| Cohort 3 | EXPERIMENTAL | Enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks |
| Cohort 4 | EXPERIMENTAL | Enoblituzumab 15 mg/kg IV plus retifanlimab 375 mg IV every 3 weeks |
| Melanoma Cohort | EXPERIMENTAL | Enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks |
| Urothelial Cancer Cohort | EXPERIMENTAL | Enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks |
| Non-small Cell Cancer (NSCLC) Cohort | EXPERIMENTAL | Enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks |
| Squamous Cell Cancer of Head and Neck (SCCHN) Cohort | EXPERIMENTAL | Enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks |
| Name | Type | Description |
|---|---|---|
| Enoblituzumab Schedule 1 | BIOLOGICAL | enoblituzumab is administered by IV infusion once per week for up to 51 doses. |
| Pembrolizumab | BIOLOGICAL | Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses. |
| Enoblituzumab Schedule 2 | BIOLOGICAL | Enoblituzumab is administered by IV infusion every 3 weeks for up to 17 doses |
| retifanlimab | BIOLOGICAL | Retifanlimab is administered by IV infusion every 3 weeks for up to 17 doses |
Inclusion Criteria: * To enroll on cohorts 1-4, participants must have a histologically-proven, previously treated, unresectable, locally advanced or metastatic mesothelioma, urothelial cancer, thyroid cancer, pancreatic cancer, ovarian cancer, colon cancer, prostate cancer, soft tissue sarcoma, tr...
Top 20 of 51 competitors
Enoblituzumab is an investigational monoclonal antibody being studied for the treatment of melanoma. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being evaluated for its safety and potential efficacy in patients with refractory cancer, including melanoma.
Enoblituzumab is a monoclonal antibody designed to target a specific antigen on cancer cells. As a monoclonal antibody, it works by binding to its target to potentially induce an immune response against the tumor. The exact molecular target has not been specified in the available information.
Enoblituzumab is being developed by MacroGenics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol MGNX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in various cancer types, including melanoma.
Enoblituzumab is currently in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical evaluation for the treatment of melanoma and other cancers.
Enoblituzumab has been studied in a Phase 1 clinical trial with the identifier NCT02475213. This trial, titled 'Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer,' enrolled 146 participants and has been completed. The study was conducted in the United States and included patients with melanoma, head and neck cancer, non-small cell lung cancer, and urothelial carcinoma.
Yes, Enoblituzumab is also known as MGA271. The clinical trial NCT02475213 refers to the drug as Enoblituzumab (MGA271), confirming that these names refer to the same investigational monoclonal antibody being developed by MacroGenics.